Biohaven Pharmaceuticals
Biohaven Pharmaceuticals is a biopharmaceutical company that develops product candidates targeting neurological diseases and rare disorders in the United States.
All edits
Biohaven Pharmaceutical Holding Company Biohaven Pharmaceuticals
BiopharmaceuticalBiohaven Pharmaceuticals is a biopharmaceutical company, that develops productsproduct candidates targeting neurological diseases and rare disorders in the United States.
ABOUT BIOHAVEN
Biohaven is a clinical-stage biopharmaceutical company with proven leadership in industry and academic settings. Our portfolio is comprised of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, including rare disorders. Our progress is fueled by an entrepreneurial organizational structure and an impressive range of experience in drug development along with the confident support of top-tier biopharma investors.
Biohaven has combined internal development and research with intellectual property licensed from companies and institutions including Bristol-Myers Squibb Company, AstraZeneca AB, Yale University, Catalent, ALS Biopharma LLC and Massachusetts General Hospital.
Since our initial public offering in 2017, we have made rapid progress with multiple compounds across our CGRP receptor antagonist, glutamate modulator, and myeloperoxidase (MPO) inhibitor platforms. Nurtec™ ODT (Rimegepant 75 mg) received FDA approval in February 2020 and is quickly gaining traction as the only orally disintegrating CGRP antagonist for acute treatment of migraine. At the same time, Biohaven is advancing novel acute and preventive treatments for migraine with zavegepant and rimegepant. In addition to continued exploration of our CGRP receptor antagonists , multiple clinical trials are ongoing for product candidates across our neuroinnovative platforms. More information can be found on our pipeline page.
Biohaven Pharmaceutical Holding Company Biohaven Pharmaceutical Holding Company
Biopharmaceutical company, develops products candidates targeting neurological diseases and rare disorders in the United States
ABOUT BIOHAVEN
Biohaven is a clinical-stage biopharmaceutical company with proven leadership in industry and academic settings. Our portfolio is comprised of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, including rare disorders. Our progress is fueled by an entrepreneurial organizational structure and an impressive range of experience in drug development along with the confident support of top-tier biopharma investors.
Biohaven has combined internal development and research with intellectual property licensed from companies and institutions including Bristol-Myers Squibb Company, AstraZeneca AB, Yale University, Catalent, ALS Biopharma LLC and Massachusetts General Hospital.
Since our initial public offering in 2017, we have made rapid progress with multiple compounds across our CGRP receptor antagonist, glutamate modulator, and myeloperoxidase (MPO) inhibitor platforms. Nurtec™ ODT (Rimegepant 75 mg) received FDA approval in February 2020 and is quickly gaining traction as the only orally disintegrating CGRP antagonist for acute treatment of migraine. At the same time, Biohaven is advancing novel acute and preventive treatments for migraine with zavegepant and rimegepant. In addition to continued exploration of our CGRP receptor antagonists , multiple clinical trials are ongoing for product candidates across our neuroinnovative platforms. More information can be found on our pipeline page.
Biohaven Pharmaceutical Holding Company
Biohaven Pharmaceuticals is a biopharmaceutical company that develops product candidates targeting neurological diseases and rare disorders in the United States.
Find more companies like Biohaven Pharmaceuticals
